Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) for Participating Patients in Tumour Necrosis Factor Receptor Fusion Protein (TNFR:Fc) Clinical Trials.
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Juvenile rheumatoid arthritis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2009 Actual patient number (639) added as reported by ClinicalTrials.gov.